FOLFIRI化疗方案及其与西妥昔单抗联用治疗晚期结肠癌分析

目的比较西妥昔单抗（爱必妥）联合FOLFIRI化疗方案治疗晚期结肠癌与单纯FOLFIRI化疗方案治疗晚期结肠癌的疗效。方法将我院2008年1月至2009年12月58例采用西妥昔单抗联合FOLFIRI化疗治疗的结肠癌患者作为观察组，将我院2006年1月至2007年12月只使用了FOLFIRI化疗方法治疗的49例结肠癌患者作为对照组。比较两组患者的治疗后生存状况。结果观察组的病情缓解率和治疗后生存质量都好于对照组，毒副作用两组患者反应都不明显。结论FOLFIRI方案联合西妥昔单抗治疗晚期结肠癌，比单独的FOLFIRI化疗方案取得了更好的治疗效果，可明显缓解患者病情，提高患者生存率和生活质量，毒副反应也较轻，处于患者可耐受范围之内。

Analysis of FOLFIRI Chemotherapy Regimen and Cetuximab in the Treatment of Advanced Colorectal Cancer

Objective To compare the curative effect between the cetuximab combined with FOLFIRI regimen and single FOLFIRI chemotherapy regimen in the treatment of advanced colorectal cancer. Methods 58 patients with colon cancer in our hospital from January 2008 to December 2009 treated with cetuximab combined with FOLFIRI chemotherapy were selected as the observation group, and 49 patients with colon cancer treated with single FOLFIRI chemotherapy regimen in our hospital from January 2006 to December 2007 were selected as the control group. The living situation after treatment between the two groups was compared. Results The remission rate and postoperative survival quality of the observation group were better than that of the control group; the toxic and side effect were not obvious in both groups. Conclusions FOLFIRI scheme combined with cetuximab has better curative effect in the treatment of advanced colon cancer than chemotherapy alone, which can obviously alleviate the patients＇ disease, improve patients＇ survival rate and quality of life, with lighter toxic reactions and patients＇ tolerance.